Catalyst CEL Fund (the “Fund”) is pleased to announce the investment in Eloxx Pharmaceuticals Limited (“Eloxx” or the “Company”), a clinical stage company developing therapeutics for genetic diseases caused by non-sense mutations. Catalyst CEL Fund is one of the lead investors together with Israeli life sciences venture capital fund Pontifax and other leading industry players in a $24 million USD investment round.
Eloxx Pharmaceuticals is a biopharmaceutical company committed to treating patients suffering from rare and ultra-rare genetic diseases caused by premature termination codons nonsense mutation. The Company is focused on the discovery, development and commercialization of compounds for the treatment of genetic diseases, such as Cystic Fibrosis and Cystinosis.
The Company’s experienced management team is led by Founder & CEO Dr. Silvia Noiman, founder and former Executive Chairwoman of cCAM Biotherapeutics Ltd. which was acquired by Merck (NYSE:MRK) in 2015, and Predix Pharmaceuticals Ltd., bringing a small early-stage drug discovery company from inception to a $500M publicly traded multi-product company (NASDAQ, EPIX); and Chairman Dr. Robert Heft, former President, CEO, and Board Member of Enobia Pharma Inc. (Montreal, Quebec) which he sold to Alexion Pharmaceuticals Inc. for USD 1.1 Billion, the largest-ever sale of a private, pre-commercial biopharmaceutical company; as well as Pontifax, the Company’s seed investor and largest shareholder, which is a leading health care VC Fund with a highly impressive track record.
The Company entered into a merger agreement with a Sevion Therapeutics, Inc., (OTCQB: SVON) on 31st May 2017. Under the terms of the agreement, Eloxx will become a wholly owned subsidiary of Sevion. Upon completion of the transaction, Sevion will change its name to Eloxx Pharmaceuticals, Inc. and intends to apply to have its shares listed for trading on NASDAQ.
Yair Shamir, Managing Partner of Catalyst CEL Fund, said: “We are excited to be joining Eloxx on the journey of becoming a leading rare diseases company with outstanding technology and a highly qualified management team. We believe that Eloxx is on track to become the innovative leader in the development of drugs addressing rare and ultra-rare genetic diseases, based on the Company’s unique abilities to restore full-length functional proteins in genetic diseases.”
Shengyan Fan, Head of Merger and Acquisition Department at China Everbright Limited and Managing Partner of Catalyst CEL Fund noted, “Eloxx’s pioneering approach in the treatment of rare and ultrarare genetic diseases and the its impressive drug development milestones, position the Company to become the lead innovator in this field. Silvia together with her team are some of the industry’s best and we are proud to join hands with them to support their work in this area.”
Silvia Noiman, Founder & CEO of Eloxx said: “The Company targets to initiate multiple clinical studies for ELX-02, our lead development candidate. Importantly, we anticipate achieving substantial clinical milestones over the course of 2017 and 2018 particularly in our lead clinical programs in cystic fibrosis and cystinosis patients carrying non-sense mutations. We are looking forward to working with the Fund’s team.”
Eloxx is the fifth investment made by the Catalyst CEL Fund. Its previous investments include Lamina Technologies, a manufacturer of state-of-the-art, precision carbide metal cutting tools, XJet, the world’s pioneering technology of inkjet-based 3D printing system for metal and ceramic parts, Taboola, a leading Israeli-founded and US-based online content discovery platform and SatixFy, a leading provider of satellite and quasi-satellite communication technology.
About Catalyst CEL Fund
The Catalyst CEL Fund, jointly managed by Catalyst and China Everbright Limited (CEL, 165.HK), primarily invests in mid-to-late stage companies with proven innovation and global presence, whose growth strategy is oriented towards activities in emerging markets with a special focus on the Greater China market. The Fund focuses on a wide variety of sectors such as manufacturing, healthcare, agriculture, technology, and telecommunication among other fields.
About Catalyst Equity Management Limited
Catalyst Equity Management Ltd. is a top performing Israeli based private equity multi-fund firm. The Catalyst team has an established track record, has been working together since 1999 and has executed three top performing funds. With over US$200 million committed capital under management, Catalyst supports the long-term growth of innovative Israeli middle-market companies in global markets. The partners enjoy a global and multi-disciplinary background, wide-reaching operational, financial and sector expertise, significant business networks and a vast transactional experience in global capital markets and cross-border M&A. The partners of Catalyst include Edouard Cukierman, Yair Shamir, Boaz Harel and Olga Bermant-Stern.
About China Everbright Limited
China Everbright Limited (“CEL”, stock code: 165.HK) is the largest overseas financial platform of China Everbright Group Ltd. (“Everbright Group”). It is the second-largest shareholder of Everbright Securities (stock code: 601788.SH, 6178.HK) and a strategic shareholder of China Everbright Bank (stock code: 601818.SH, 6818.HK), the controlling shareholder of the Hong Kong-listed China Aircraft Leasing Group Holdings Limited (stock code: 1848.HK), the largest shareholder of Shanghai Jiabao Industry & Commerce (Group) Co., Ltd (stock code: 600622.SH), and the second-largest shareholder of the Singapore-listed Ying Li International Real Estate Limited (stock code: 5DM. SGX). As at end June 2016, CEL managed 33 funds with a total fundraising amount of more than HK$67.8 billion. Everbright Group, the parent company of CEL, is a state-owned financial conglomerate with AUM of approximately RMB3,000 billion as at end-2015. For more information about CEL, please visit www.everbright165.com.
For more information, please contact:
Catalyst Private Equity
Tamar Ayalon, POSITIVE PR,